Warning lights
Signals from the annual accounts, the CBE and the Official Gazette, each with its threshold and source. No score, no verdict.
-
Tight liquidity NBB
Cash and receivables cover 52 % of short-term debt in 2025; threshold 65 %.
-
Not on Peppol Peppol
Not registered in the Peppol network, mandatory for VAT-liable companies since 1 January 2026.
Financials
Financial year 2025
Biocytom GBX from Gembloux, company number BE0543497928, closed financial year 2025 with a result of € 117,830 after tax. For that financial year Biocytom GBX recorded a gross margin of € 190,033 and equity of € 587,744. Compared with financial year 2024, the result moved from € 85,208 to € 117,830. Profitable, and profit is growing. The company holds a healthy buffer. A strong own buffer against the debts. The most recent annual accounts were filed with the National Bank of Belgium on May 27, 2026.
€ 587,744
▼ 12% vs 2024
Assets minus debts, by the books. What is left if everything were sold and paid today.
€ 117,830
▲ 38% vs 2024
Profit after tax over the fiscal year.
€ 428,934
▲ 34% vs 2024
Cash and bank balances on the last day of the fiscal year.
€ 200,000 paid out
More than the year’s profit went to the shareholders; reserves fell.
People and assets in 2025
€ 16,070
▼ 28% vs 2024
Book value of vehicles, furniture and equipment.
Debts at end 2025
None
No bank loans on the last day of the fiscal year.
€ 520
▲ € 474 vs 2024
Supplier invoices still open on the last day of the fiscal year.
€ 13,857
▲ 9% vs 2024
Corporate tax and VAT still to pay. No wage debt: nothing outstanding to staff or social security.
Want to see how much further we take a dossier in the Pro version? Open the free De Lijn example and give feedback →
| 2022 | 2023 | 2024 | 2025 | Change 2024 → 2025 | |
|---|---|---|---|---|---|
| Gross margin | € 186,651 | € 144,941 | € 140,552 | € 190,033 | ▲ 35% |
| Profit after taxes | € 122,470 | € 90,000 | € 85,208 | € 117,830 | ▲ 38% |
| Equity | € 494,706 | € 584,706 | € 669,914 | € 587,744 | ▼ 12% |
| Total debts | € 493,582 | € 532,087 | € 591,689 | € 850,746 | ▲ 44% |
| Cash | € 478,558 | € 209,801 | € 319,982 | € 428,934 | ▲ 34% |
| Retained profit | € 476,106 | € 566,106 | € 651,314 | € 569,144 | ▼ 13% |
| Dividend | € 0 | € 0 | € 0 | € 200,000 | |
| Balance sheet total | € 988,288 | € 1,116,793 | € 1,261,604 | € 1,438,490 | ▲ 14% |
Key figures of Biocytom GBX, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.
What happened to Biocytom GBX?
What happened at Biocytom GBX in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- New annual accounts for financial year 2025: profit of € 117,830 (▲ 38% vs 2024). Source: NBB ↗
- New establishment in Gembloux. KBO
- Philippe DUPRET became a director. NBB
- Start of the company according to the CBE. KBO
In short
From € 122,470 profit in 2022 to € 117,830 profit in 2025.
Paid € 109,965 in corporate taxes since 2022.
Best year ever: 2022, with € 122,470 profit.
Paid out € 200,000 in dividends to the owners in total.
A new publication or filing at Biocytom GBX? We notify you, reason included.
Follow Biocytom GBXDatabakkes Pro
Know what changes at your customers, suppliers and competitors. Without reading an annual account.
- Follow them in one folder Every company in your folder gets this full dossier: household book, all fiscal years, benchmark against companies of the same size.
- We alert you, with the reason New annual account, Official Gazette publication or status change: you get what changed and where it says so.
- In bulk too, and in ChatGPT and Claude Upload your customer list and get the warning signs back per company. Or ask in your own AI assistant, with this register as the source.
Databakkes Pro is being built. Sign up now and you are first in line for an invitation, with a month to try without a credit card.
De Lijn 8 June 2026 New annual account 2025
filed on 8 June 2026
What was left
€ 20 k ▼ 91%
Money in the bank
€ 178 k ▼ 98%
Open the dossier →
NMBS 8 June 2026 New annual account 2025 What was left ▼ 80%
bpost 18 May 2026 New annual account 2025 What was left from loss to profit
Management
Behind Biocytom GBX is Philippe DUPRET.
Directors
According to the 2025 annual accounts
Philippe DUPRET
Director
since 2013
Establishments
Establishment units
Physical locations of this company
Avenue des Combattants 44
5030 Gembloux
What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Details
- Company number
- 0543.497.928
- VAT number
- BE 0543.497.928
- Registered office
- Avenue des Combattants 44, 5030 Gembloux
- Names & denominations
- Biocytom GBX
- Enterprise type
- Rechtspersoon
- Legal form
- Private limited company
- Legal situation
- Normale toestand
- Start date
- 20 December 2013
- Peppol
- Not registered
- Activities · NACE
Activiteiten van medische beeldvorming en medische laboratoria
Activiteiten van medische laboratoria